^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Solid Tumor
    Drug:CT-0508 (HER2 inhibitor, Macrophage stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

    Excerpt:
    ...- HER2-positive recurrent or metastatic solid tumors for which there are...
    Trial ID:
    NCT04660929
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    J Transl Med
    Title:

    M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors

    Published date:
    03/28/2023
    Excerpt:
    We demonstrated that our novel CAR-M can effectively eliminate HER2-positive tumor cells both in vitro and in vivo, and M1 polarization significantly enhanced the antitumor ability of CAR-M, resulting in a stronger therapeutic effect in solid cancer immunotherapy.
    DOI:
    10.1186/s12967-023-04061-2